RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Fusion Antibodies Stock

Fusion Antibodies Market capitalization 2024

Fusion Antibodies Market capitalization

858,493.35 GBP

Ticker

FAB.L

ISIN

GB00BDQZGK16

In 2024, Fusion Antibodies's market cap stood at 858,493.35 GBP, a -39.78% increase from the 1.43 M GBP market cap in the previous year.

The Fusion Antibodies Market capitalization history

YEARMarket Capitalization (undefined GBP)
20235.18
202215.92
202133.34
202023.46
201912.84
201817.36
201739.61
2016-
2015-

Fusion Antibodies Aktienanalyse

What does Fusion Antibodies do?

The company Fusion Antibodies PLC is a biotechnology company specializing in the production of antibodies for medical and scientific research. The company, based in Belfast, Northern Ireland, was founded in 2001 and has been listed on the London Stock Exchange since 2017. Fusion Antibodies' business model is based on the development of customized antibodies for customers in the pharmaceutical, biotech, diagnostics, and academic research sectors. The company offers a wide range of services throughout the entire antibody development process, from antigen design to the production of recombinant antibodies and antibody conjugates. Fusion Antibodies divides its business operations into three main departments: antibody engineering, antibody production, and antibody conjugation. The antibody engineering department is involved in the discovery and optimization of antibodies using advanced technologies such as phage display and hybridoma technologies. In the antibody production department, the desired antibodies are produced through cell culture or recombinant technologies. Finally, in the antibody conjugation department, the antibody is coupled with other molecules such as enzymes, toxins, or fluorescent dyes to generate new therapeutic agents or diagnostic systems. Fusion Antibodies also offers a variety of products that can be either individually configured by customers or purchased as standard products. The portfolio of standard products includes antibodies against known target molecules such as GFP, His-tag, and HA-tag, as well as antibodies tailored to specific applications such as anti-idiotypic antibodies or antibodies for the detection of posttranslational modifications of proteins. In addition, Fusion Antibodies also offers a customized service for the production of antibodies against customer-specific target molecules, tailored to the individual needs of the customer. Fusion Antibodies has numerous customers from the biopharmaceutical and biotechnology industry, as well as from academic research. The company works closely with its customers to meet their specific requirements and offers flexibility and a creative approach through its technology platform in developing solutions for their challenges. The company has a strong R&D department and continuously invests in the development of new technologies and products to maintain and expand its competitiveness. Fusion Antibodies also has partnerships with other companies and institutions in the biotech industry to jointly develop new technologies and products. Overall, Fusion Antibodies is an innovative company specializing in the development of antibodies for use in medical and scientific research. Through its wide range of services, products, and partnerships, the company has solidified its position in the biotech industry and is expected to continue to play an important role in the development of new therapeutic and diagnostic approaches. Fusion Antibodies ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Market capitalization Details

Exploring Fusion Antibodies's Market Capitalization

Fusion Antibodies's market capitalization represents the total dollar market value of the company’s outstanding shares of stock. It is calculated by multiplying the company's shares outstanding by the current market price of one share. This metric is a vital indicator of a company’s size, strength, and overall market value.

Year-to-Year Comparison

A yearly comparison of Fusion Antibodies's market capitalization provides investors and analysts insights into its growth and valuation trends. An increase signifies market confidence and business expansion, while a decrease may point towards declining market value or business contractions.

Impact on Investments

Fusion Antibodies's market capitalization plays a pivotal role in investment decisions. It aids investors in assessing the company's risk and return profiles. Larger companies are often considered more stable but may offer lower growth potential, while smaller companies might offer significant growth prospects but come with higher risk.

Interpreting Market Capitalization Fluctuations

Variations in Fusion Antibodies’s market capitalization can be attributed to several factors, including changes in stock price, outstanding shares, and market sentiment. Understanding these fluctuations helps investors evaluate the company's current standing and future potential in the competitive landscape.

Frequently Asked Questions about Fusion Antibodies stock

What is the current Fusion Antibodies market capitalization?

The current market capitalization of Fusion Antibodies is 858,493.35 GBP.

What is market capitalization?

The market capitalization (German: Marktkapitalisierung, English: market capitalization, abbreviated as market cap, also known as stock exchange capitalization or market value) is the calculated total value of all shares of a publicly traded company like Fusion Antibodies.

How has the market capitalization of Fusion Antibodies developed in recent years?

The market capitalization of Fusion Antibodies has increased/decreased by -39.78% compared to the previous year.

What does market capitalization mean for investors?

The market capitalization of a company reflects the current market consensus on the value of the equity of a publicly traded company.

Why is market capitalization an important indicator for investors?

The market capitalization of a company reflects the current market consensus on the value of a publicly traded company's equity. It is determined by the supply and demand for the company's shares. Market capitalization is thus significantly influenced by expectations in the stock market regarding the future earnings power of the company, and as such, it can undergo significant fluctuations.

Why does the market capitalization fluctuate?

The market capitalization fluctuates along with the stock price, as the market capitalization is calculated based on the current price and the number of outstanding shares.

What role does market capitalization play in the valuation of Fusion Antibodies?

In order to compare the value of companies, it is helpful to consider not only the market capitalization but also the net debt of a company. A potential buyer of the entire company would also acquire the debts of the company. The enterprise value is the total value of a company or a stock corporation. The net financial indebtedness of the company is added to the market capitalization.

Does the market capitalization influence the performance of Fusion Antibodies?

There is no verifiable long-term evidence or study that stocks with a specific market capitalization (whether Mega/Large/Mid/Small Cap) would consistently yield significantly higher returns than others. There are occasional small studies (few stocks, short investment period) suggesting that certain classes may perform better or have higher risk, but none of them are 1. conclusive (cause-effect relationship is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

Does the market capitalization of Fusion Antibodies have an influence on indices?

Some stock indices use market capitalization as index weighting. Stocks with a higher market capitalization are also weighted higher in the index. This is in contrast to equally weighted indices (all stocks have the same weighting) and free float weighted indices (market capitalization weighting, but only with the number of shares in free float).

How much dividend does Fusion Antibodies pay?

Over the past 12 months, Fusion Antibodies paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Fusion Antibodies is expected to pay a dividend of 0 GBP.

What is the dividend yield of Fusion Antibodies?

The current dividend yield of Fusion Antibodies is .

When does Fusion Antibodies pay dividends?

Fusion Antibodies pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Fusion Antibodies?

Fusion Antibodies paid dividends every year for the past 0 years.

What is the dividend of Fusion Antibodies?

For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.

In which sector is Fusion Antibodies located?

Fusion Antibodies is assigned to the 'Health' sector.

Wann musste ich die Aktien von Fusion Antibodies kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Fusion Antibodies from 9/9/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 9/9/2024.

When did Fusion Antibodies pay the last dividend?

The last dividend was paid out on 9/9/2024.

What was the dividend of Fusion Antibodies in the year 2023?

In the year 2023, Fusion Antibodies distributed 0 GBP as dividends.

In which currency does Fusion Antibodies pay out the dividend?

The dividends of Fusion Antibodies are distributed in GBP.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Fusion Antibodies

Our stock analysis for Fusion Antibodies Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Fusion Antibodies Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.